DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. announced today that it will have multiple presentations at the American Association for Cancer Research Annual Meeting on April 14-18 in Los Angeles. These presentations will focus on data concerning many of SuperGen's current oncology programs including its lead tyrosine kinase inhibitor compound, MP470 and its ability to block Rad51, a key protein target involved in cancer cell drug resistance. Presentations will take place in the exhibit hall of the Los Angeles Convention Center.
The schedule of SuperGen's presentations is: Poster Date Time (PDT) Title Number/Section Sunday, 1 p.m. - 5 p.m. Hydrochloride salt of #1540 April MP470, a potent 15 suppressor of Rad51, Poster improves Section 31 bioavailability and tolerability Monday, 8 a.m. - 12 p.m. Discovery and #2380 April characterization of a 16 series of Axl kinase Poster inhibitors using the Section 30 CLIMB(TM) process Monday, 8 a.m. - 12 p.m. Discovery and #2387 April characterization of 16 small molecule Poster inhibitors for Jak2 Section 30 Monday, 8 a.m. - 12 p.m. Zebrafish as a model #2229 April mechanistic screen 16 for small molecule Poster inhibitors of DNMT1 Section 23 Monday, 1 p.m. - 5 p.m. Discovery and #3261 April development of MP529, 16 a new effective and Poster selective inhibitor Section 29 of Aurora A kinase Tuesday, 8 a.m. - 12 p.m. MP470, a potent #4028 April suppressor of Rad51, 17 improves response to Poster platinum-based Section 29 anticancer agents Tuesday, 10:40 a.m. - Novel DNA #4142 April 10:55 a.m. hypomethylating 17 agents: non- Minisymposium nucleoside compounds Cancer that do not Epigenetics incorporate into DNA selectively induce Room 304 A-C degradation of DNA methyltransferase I (DNMT1) in human cancer cells by the proteasomal pathway and re-express silenced tumor suppressor genes Wed., 8 a.m. - 12 p.m. Dual inhibition of #5421 April receptor tyrosine 18 kinases of PDGFR and Poster EGFR abolishes Section 20 prostate cancer cell growth in culture and in a mouse xenograft model by complete dephosphorylation of PKB/Akt About SuperGen
Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts: SuperGen Noonan Russo Timothy L. Enns Greg Geissman S.V.P., Corporate Communications Director of Media Relations & Business Development (925) 560-0100 x111 (619) email@example.com firstname.lastname@example.org
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, of SuperGen, +1-925-560-0100 x111, ; or GregGeissman, Director of Media Relations, of Noonan Russo, +1-619-814-3510, email@example.com firstname.lastname@example.org
Web site: http://www.supergen.com/
Ticker Symbol: (NASDAQ-NMS:SUPG)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company